Medicus Pharma Ltd. (MDCX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US58471K2024
Medicus Pharma Ltd. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -34.36 m USD |
| EBIT | -47.28 m USD |
| Net income | -47.28 m USD |
| Diluted EPS – continuing operations | -2.74 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Medicus Pharma Ltd.
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
More stocks
- Beyond Air, Inc. (XAIR)
- CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH)
- Indaptus Therapeutics, Inc. (INDP)
- MacKenzie Realty Capital, Inc. (MKZR)
- Quest Water Global, Inc. (QWTR)
- AIRWA INC. (YYAI)
- Wenyuan Group Corp. (WYGC)
- VITASPRING BIOMEDICAL CO. LTD. (VSBC)
- NOCERA, INC. (NCRA)
- Vemanti Group, Inc. (VMNT)
- CHASE PACKAGING CORP (WHLT)
- Fly-E Group, Inc. (FLYE)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.